H.R. 3520House116th Congress (2019-2021)In Committee

Stem Cell Therapeutic and Research Reauthorization Act of 2019

Introduced June 26, 2019

AI-Generated Summary

Updated April 14, 2026 at 6:41 AM UTC

The Stem Cell Therapeutic and Research Reauthorization Act of 2019 extends the authorizations in the 2005 law that supports stem cell therapies and research. It updates funding for the C.W. Bill Young Cell Transplantation Program and the national cord‑blood inventory, and adds a requirement that the program’s advisory council meet at least twice each year. The changes affect federal agencies that run these programs and the researchers and patients who rely on them.

Key Provisions

  • Amends the Public Health Service Act to clarify that cell collection may include remote collection, consistent with inventory requirements.
  • Requires the Secretary to convene the program’s Advisory Council at least two times per calendar year.
  • Sets funding for the C.W. Bill Young Cell Transplantation Program at $30 million annually for fiscal years 2020‑2024 (replacing earlier amounts).
  • Authorizes $23 million each year for fiscal years 2020‑2024 to support the national cord‑blood inventory.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions
HouseCommittee Latest Action

Referred to the Subcommittee on Health.

June 27, 2019

View full timeline
HouseIntro Referral

Introduced in House

June 26, 2019

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

June 26, 2019

HouseCommittee

Referred to the Subcommittee on Health.

June 27, 2019

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued June 26, 2019

I

116th CONGRESS

1st Session

H. R. 3520

IN THE HOUSE OF REPRESENTATIVES

June 26, 2019

Mr. Smith of New Jersey (for himself and Mr. Bilirakis) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

1.

Short title

This Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2019.

2.

Reauthorization of the C.W. Bill Young Cell Transplantation Program

(a)

In general

Section 379(d)(2)(B) of the Public Health Service Act (42 U.S.C. 274k(d)(2)(B)) is amended—

(1)

by striking including remote collection, consistent with the inventory and inserting including collection, consistent with the inventory; and

(2)

by inserting including remote collection, before consistent with the requirements.

(b)

Advisory council meetings

Subsection (a) of section 379 of the Public Health Service Act (42 U.S.C. 274k) is amended by adding at the end the following new paragraph:

(7)

The Secretary shall convene the Advisory Council at least two times each calendar year.

.

(c)

Authorization of appropriations

Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended by striking $33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020 and inserting $30,000,000 for each of fiscal years 2020 through 2024.

3.

Cord blood inventory

Subsection (g) of section 2 of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended to read as follows:

(g)

Authorization of appropriations

To carry out this section, there is authorized to be appropriated $23,000,000 for each of fiscal years 2020 through 2024.

.